Neurobiology of Suicide

PHASE2RecruitingINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

July 21, 2026

Study Completion Date

July 21, 2026

Conditions
Healthy VolunteersDepression
Interventions
DEVICE

Magnetic Resonance Imaging scanner, 3T

Non-significant risk device used for brain imaging.

DEVICE

NeurOptics PLRTM-3000 Pupillometer

The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.

DEVICE

Experimental Anxiety Devices

Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.

DEVICE

Magnetic Resonance Imaging scanner, 7T

Non-significant risk device used for brain imaging.

DRUG

Ketamine Hydrochloride

A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT02543983 - Neurobiology of Suicide | Biotech Hunter | Biotech Hunter